This form collects the information required to refer patients for consultation with a specialist in the initiation of Repatha® therapy for insurance and coverage purposes.
Interactive resources about cholesterol, CV disease and risk factors. Learn about the role of Repatha® as a treatment option, and what to expect when taking Repatha® (evolocumab).
This informational guide to the Repatha® Co-Pay Card includes program details, eligibility criteria, and how to get started.
This resource provides an easy-to-use guide to the ICD-10 codes relevant to Repatha®.
A guide to help you and your office staff help patients start and stay on Repatha®, including where to find tools, resources, prior authorization support, ICD-10 codes, and Co-Pay card information.
This sample letter is a template to explain the clinical rationale for prescribing Repatha®. This should accompany a prior authorization.
This sample letter is a template to explain the clinical rationale for prescribing Repatha®. This can be used during the appeals process.
This checklist can organize specific information about patients’ diagnosis and treatment history to help complete a prior authorization.
This brochure provides an overview of the increasing access and affordability of Repatha® over the years.
Resources for patients starting on Repatha® including how to fill a Repatha® prescription, what to expect, and injection information. Hear directly from Repatha® patients and their experience with treatment.
A resource designed to help patients learn more about treatment with Repatha®.
Download a Co-Pay card guide for complete program information or click the button below to learn more.
Watch a video on how to inject with the Repatha® SureClick® Device (140 mg/mL single-dose prefilled autoinjector).
Watch a video on how to inject with the Repatha® Pushtronex® Device (420 mg/3.5 mL single-dose on-body infusor with prefilled cartridge).
NRx, new prescription; PCSK9, proprotein convertase subtilisin/kexin type 9; PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor.
Contraindications: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.
From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).
Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.
Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.
Repatha® is indicated: